PDCD1 and neoplasm: However, it was reported that the effectiveness of immune checkpoint inhibitors, such as anti-PD-1 antibodies, is notably diminished in “cold” tumors, characterized by a scarcity of immune cells within the tumor microenvironment [33,34].